查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
出血性疾病治療藥的全球市場 (～2027年):各藥物類型、疾病類型、流通管道、終端用戶、地區的競爭、機會、預測
市場調查報告書
商品編碼
1121071

出血性疾病治療藥的全球市場 (～2027年):各藥物類型、疾病類型、流通管道、終端用戶、地區的競爭、機會、預測

Global Bleeding Disorders Treatment Market By Drug Type, By Disease Type, By Distribution Channel, By End User By Region, Competition, Forecast & Opportunities, 2027
出版日期: | 出版商: TechSci Research | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球出血性疾病治療藥的市場，從預測期間的2023年到2027年預計記錄穩定的年複合成長率。

患者人口增加，公民營的經營者的醫療支出增加，中游家庭的可支配所得增加等要素牽引該市場。還有R&D活動的進展，及製藥公司著重基因改造產品，今後5年預計創造市場有利的成長機會。

本報告提供全球出血性疾病治療藥的市場調查，市場概要，市場規模的變化、預測，各種區分、各地區/主要國家的明細，市場的各種影響因素的分析，競爭環境，市場佔有率，主要企業簡介等彙整資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 摘要整理

第4章 COVID-19:對全球出血性疾病治療藥市場的影響

第5章 VOC (客戶的迴響)

第6章 全球出血性疾病治療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各藥物類型(血漿來源凝固凝血因子濃縮劑、重組凝固凝血因子濃縮劑、去氨加壓素、抗線溶藥、纖維蛋白膠、其他)
    • 各疾病類型(A型血友病、B型血友病、類血友病病、其他)
    • 各流通管道(醫院藥局、零售藥局、線上)
    • 各終端用戶(診所、醫院、研究機關、其他)
    • 各企業
    • 各地區(北美、歐洲、亞太地區、南美、中東&非洲)
  • 產品市場地圖

第7章 北美的出血性疾病治療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各藥物類型
    • 各疾病類型
    • 各流通管道
    • 各終端用戶
    • 各國
  • 各國分析

第8章 歐洲的出血性疾病治療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各藥物類型
    • 各疾病類型
    • 各流通管道
    • 各終端用戶
    • 各國
  • 各國分析

第9章 亞太地區的出血性疾病治療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各藥物類型
    • 各疾病類型
    • 各流通管道
    • 各終端用戶
    • 各國
  • 各國分析

第10章 中東及非洲的出血性疾病治療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各藥物類型
    • 各疾病類型
    • 各流通管道
    • 各終端用戶
    • 各國
  • 各國分析

第11章 南美的出血性疾病治療藥市場預測

  • 市場規模、預測
  • 市場佔有率、預測
    • 各藥物類型
    • 各疾病類型
    • 各流通管道
    • 各終端用戶
    • 各國
  • 各國分析

第12章 市場動態

  • 促進因素
  • 課題

第13章 市場趨勢、市場展開

第14章 競爭情形

  • 競爭預測
  • 全球企業簡介
    • Bayer AG
    • Pfizer Inc.
    • Grifols S.A.
    • Octapharma AG
    • Sun Pharmaceuticals Industries Ltd.
    • Ferring Pharmaceuticals SA
    • Amgen Inc.
    • Sanofi SA
    • Baxter International Inc.
    • F. Hoffmann-La Roche Ltd.
    • Takeda Pharmaceuticals Ltd.
    • Novo Nordisk A/S
    • Novartis AG
    • Eli Lilly and Company Ltd.
    • Gilead Sciences Inc.

第15章 策略性建議

第16章 關於本公司&免責聲明

簡介目錄
Product Code: 7317

The global bleeding disorders treatment market is projected to witness a steady CAGR during the forecast period, 2023-2027. Factors such as the rise in the patient population base, increased healthcare expenditure by the public and private players, and growing disposable income for middle-class families drive the global bleeding disorders treatment market. The ongoing research and development activities and the increased focus of pharmaceutical companies on recombinant products are expected to create lucrative growth opportunities for the global bleeding disorders treatment market in the next five years. However, limited reimbursement and the high cost of availing of bleeding disorder treatment facilities may hinder the market growth in the forecast period.

The global bleeding disorders treatment market is segmented into drug type, disease type, distribution channel, end user, regional distribution, and competitive landscape. Based on drug type, the market is fragmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others. The recombinant coagulation factor concentrates segment is expected to capture the highest market share during the forecast period, 2023-2027. Their high efficiency in preventing bleeding than plasma-derived coagulation factor concentrates is expected to drive the market demand in the next five years.

North America is expected to dominate the global bleeding disorders treatment market in the forecast period. The compatibility of the population of all age groups in the United States for prophylaxis treatment is driving the market demand in the region.

The major players operating in the global bleeding disorders treatment market are: Bayer AG, Pfizer Inc., Grifols S.A., Octapharma AG, Sun Pharmaceuticals Industries Ltd., Ferring Pharmaceuticals SA, Amgen Inc., Sanofi SA, Baxter International Inc., F. Hoffmann-La Roche Ltd., Takeda Pharmaceuticals Ltd., Novo Nordisk A/S, Novartis AG, Eli Lilly and Company Ltd., Gilead Sciences Inc., among others. The companies are focusing on extensive research and development activities to stay competitive in the market.

Years considered for this report:

  • Historical Years: 2017 - 2020
  • Base Year: 2021
  • Estimated Year: 2022
  • Forecast Period: 2023 - 2027

Objective of the Study:

  • To analyze and forecast the market size of global bleeding disorders treatment market from 2017 to 2021.
  • To estimate and forecast the market size of global bleeding disorders treatment market from 2022 to 2027 and growth rate until 2027.
  • To classify and forecast global bleeding disorders treatment market based on drug type, disease type, distribution channel, end user, and regional distribution.
  • To identify dominant region or segment in the global bleeding disorders treatment market.
  • To identify drivers and challenges for global bleeding disorders treatment market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Global bleeding disorders treatment market.
  • To identify and analyze the profile of leading players operating in Global bleeding disorders treatment market.
  • To identify key sustainable strategies adopted by market players in Global bleeding disorders treatment market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.

TechSci Research calculated the market size of Global bleeding disorders treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Bleeding disorders treatment vendors, end users, service providers and other stakeholders
  • Distributers and suppliers of bleeding disorders treatment's products and services and other stakeholders
  • Organizations, forums, and alliances related to bleeding disorders treatment
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, Global bleeding disorders treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By Drug Type:

  • Plasma-derived Coagulation Factor Concentrates
  • Recombinant Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants
  • Others

Market, By Disease Type:

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

Market, By End User:

  • Clinics
  • Hospitals
  • Research Institutes
  • Others

Market, By Region:

  • North America
  • APAC
  • Europe
  • MEA
  • South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global bleeding disorders treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Bleeding Disorders Treatment Market

4. Executive Summary

5. Voice of Customer

6. Global Bleeding Disorders Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others)
    • 6.2.2. By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others)
    • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)
    • 6.2.4. By End User (Clinics, Hospitals, Research Institutes, Others)
    • 6.2.5. By Company (2021)
    • 6.2.6. By Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)
  • 6.3. Product Market Map

7. North America Bleeding Disorders Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Disease Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By End User
    • 7.2.5. By Country (United States; Canada; Mexico)
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Bleeding Disorders Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Disease Type
        • 7.3.1.2.3. By Distribution Channel
        • 7.3.1.2.4. By End User
    • 7.3.2. Canada Bleeding Disorders Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Disease Type
        • 7.3.2.2.3. By Distribution Channel
        • 7.3.2.2.4. By End User
    • 7.3.3. Mexico Bleeding Disorders Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Disease Type
        • 7.3.3.2.3. By Distribution Channel
        • 7.3.3.2.4. By End User

8. Europe Bleeding Disorders Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Disease Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By End User
    • 8.2.5. By Country (France; Germany; UK; Italy; Spain)
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Bleeding Disorders Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Disease Type
        • 8.3.1.2.3. By Distribution Channel
        • 8.3.1.2.4. By End User
    • 8.3.2. Germany Bleeding Disorders Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Disease Type
        • 8.3.2.2.3. By Distribution Channel
        • 8.3.2.2.4. By End User
    • 8.3.3. United Kingdom Bleeding Disorders Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Disease Type
        • 8.3.3.2.3. By Distribution Channel
        • 8.3.3.2.4. By End User
    • 8.3.4. Italy Bleeding Disorders Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Disease Type
        • 8.3.4.2.3. By Distribution Channel
        • 8.3.4.2.4. By End User
    • 8.3.5. Spain Bleeding Disorders Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Disease Type
        • 8.3.5.2.3. By Distribution Channel
        • 8.3.5.2.4. By End User

9. Asia-Pacific Bleeding Disorders Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Disease Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By End User
    • 9.2.5. By Country (China; India; Japan; South Korea; Australia)
  • 8.3 Asia-Pacific: Country Analysis
    • 8.3.1 China Bleeding Disorders Treatment Market Outlook
      • 8.3.1.1 Market Size & Forecast
        • 8.3.1.1.1 By Value
      • 8.3.1.2 Market Share & Forecast
        • 8.3.1.2.1 By Drug Type
        • 8.3.1.2.2 By Disease Type
        • 8.3.1.2.3 By Distribution Channel
        • 8.3.1.2.4 By End User
    • 8.3.2 India Bleeding Disorders Treatment Market Outlook
      • 8.3.2.1 Market Size & Forecast
        • 8.3.2.1.1 By Value
      • 8.3.2.2 Market Share & Forecast
        • 8.3.2.2.1 By Drug Type
        • 8.3.2.2.2 By Disease Type
        • 8.3.2.2.3 By Distribution Channel
        • 8.3.2.2.4 By End User
    • 8.3.3 Japan Bleeding Disorders Treatment Market Outlook
      • 8.3.3.1 Market Size & Forecast
        • 8.3.3.1.1 By Value
      • 8.3.3.2 Market Share & Forecast
        • 8.3.3.2.1 By Drug Type
        • 8.3.3.2.2 By Disease Type
        • 8.3.3.2.3 By Distribution Channel
        • 8.3.3.2.4 By End User
    • 8.3.4 South Korea Bleeding Disorders Treatment Market Outlook
      • 8.3.4.1 Market Size & Forecast
        • 8.3.4.1.1 By Value
      • 8.3.4.2 Market Share & Forecast
        • 8.3.4.2.1 By Drug Type
        • 8.3.4.2.2 By Disease Type
        • 8.3.4.2.3 By Distribution Channel
        • 8.3.4.2.4 By End User
    • 8.3.5 Australia Bleeding Disorders Treatment Market Outlook
      • 8.3.5.1 Market Size & Forecast
        • 8.3.5.1.1 By Value
      • 8.3.5.2 Market Share & Forecast
        • 8.3.5.2.1 By Drug Type
        • 8.3.5.2.2 By Disease Type
        • 8.3.5.2.3 By Distribution Channel
        • 8.3.5.2.4 By End User

10. Middle East and Africa Bleeding Disorders Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Disease Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By End User
    • 10.2.5. By Country (UAE; Saudi Arabia; South Africa)
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bleeding Disorders Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Disease Type
        • 10.3.1.2.3. By Distribution Channel
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Bleeding Disorders Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Disease Type
        • 10.3.2.2.3. By Distribution Channel
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Bleeding Disorders Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Disease Type
        • 10.3.3.2.3. By Distribution Channel
        • 10.3.3.2.4. By End User

11. South America Bleeding Disorders Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Type
    • 11.2.2. By Disease Type
    • 11.2.3. By Distribution Channel
    • 11.2.4. By End User
    • 11.2.5. By Country (Brazil; Argentina; Colombia)
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Bleeding Disorders Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Type
        • 11.3.1.2.2. By Disease Type
        • 11.3.1.2.3. By Distribution Channel
        • 11.3.1.2.4. By End User
    • 11.3.2. Argentina Bleeding Disorders Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Type
        • 11.3.2.2.2. By Disease Type
        • 11.3.2.2.3. By Distribution Channel
        • 11.3.2.2.4. By End User
    • 11.3.3. Colombia Bleeding Disorders Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Type
        • 11.3.3.2.2. By Disease Type
        • 11.3.3.2.3. By Distribution Channel
        • 11.3.3.2.4. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Global Players Profiled (Leading Companies)
    • 14.2.1. Bayer AG
    • 14.2.2. Pfizer Inc.
    • 14.2.3. Grifols S.A.
    • 14.2.4. Octapharma AG
    • 14.2.5. Sun Pharmaceuticals Industries Ltd.
    • 14.2.6. Ferring Pharmaceuticals SA
    • 14.2.7. Amgen Inc.
    • 14.2.8. Sanofi SA
    • 14.2.9. Baxter International Inc.
    • 14.2.10. F. Hoffmann-La Roche Ltd.
    • 14.2.11. Takeda Pharmaceuticals Ltd.
    • 14.2.12. Novo Nordisk A/S
    • 14.2.13. Novartis AG
    • 14.2.14. Eli Lilly and Company Ltd.
    • 14.2.15. Gilead Sciences Inc.

15. Strategic Recommendations

16. About Us & Disclaimer